Altre lingue Gene Biotherapeutics, Inc.

Azioni

CRXM

US8767671048

Mercato chiuso - OTC Markets Altri mercati azionari 20:22:26 09/02/2024			Variaz. 5gg	Var. 1 gen.
0,000001 ^USD	-.--%		-.--%	-.--%

2022	Gene Biotherapeutics, Inc. Il revisore dei conti solleva dubbi sulla continuità aziendale	CI
2021	Gene Biotherapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2020	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	14/04/22
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	30/03/22
Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/22
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	27/10/21
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	03/09/21
Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	03/09/21
GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)	09/08/21
GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	05/08/21
GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	28/07/21
Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board	28/07/21
GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	26/04/21
Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product	26/04/21
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23/04/21
GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	28/05/20
Gene Biotherapeutics, Inc. Announces Management Changes	28/05/20
Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer	28/05/20
Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC	22/05/20
Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors	20/03/19
Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc	13/09/18
Gene Biotherapeutics Mulls Acquisitions	08/01/18

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Gene Biotherapeutics, Inc.

Azioni

CRXM

US8767671048

Altre lingue

Filtri